[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Alwis G, Linden C, Dencker M, Stenevi-Lundgren S, Gardsell P, Karlsson MK: Bone mineral accrual and gain in skeletal width in pre-pubertal school children is independent of the mode of school transportation--one-year data from the prospective observational pediatric osteoporosis prevention (POP) study. BMC Musculoskelet Disord; 2007;8:66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral accrual and gain in skeletal width in pre-pubertal school children is independent of the mode of school transportation--one-year data from the prospective observational pediatric osteoporosis prevention (POP) study.
  • METHODS: Ninety-seven girls and 133 boys aged 7-9 years were recruited as a part of the Malmö Pediatric Osteoporosis Prevention (POP) Study in order to evaluate the influence of self-selected school transportation for the accrual of bone mineral and bone width.
  • Bone mineral content (BMC) was measured by dual energy X-ray absorptiometry (DXA) in the lumbar spine (L2-L4), third lumbar vertebra (L3) and hip, and bone width was calculated at L3 and femoral neck (FN).

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 5;355(9202):469-70 [10841134.001]
  • [Cites] J Bone Miner Res. 2005 Jun;20(6):906-12 [15883629.001]
  • [Cites] Res Q Exerc Sport. 2000 Jun;71(2 Suppl):S1-14 [10925819.001]
  • [Cites] J Pediatr. 2001 Oct;139(4):501-8 [11598595.001]
  • [Cites] Br J Sports Med. 2002 Aug;36(4):250-7; discussion 257 [12145113.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):555-63 [1874933.001]
  • [Cites] Bone Miner. 1992 Apr;17(1):75-85 [1581707.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1060-5 [1400871.001]
  • [Cites] Calcif Tissue Int. 1993 Jul;53(1):7-12 [8348387.001]
  • [Cites] Bone Miner. 1993 Dec;23(3):171-82 [8148662.001]
  • [Cites] Ann Intern Med. 1995 Jul 1;123(1):27-31 [7762910.001]
  • [Cites] J Bone Miner Res. 1998 Feb;13(2):310-9 [9495526.001]
  • [Cites] Med Sci Sports Exerc. 1998 Apr;30(4):629-33 [9565947.001]
  • [Cites] Eur J Radiol. 1998 Sep;28(2):150-4 [9788020.001]
  • [Cites] J Bone Miner Res. 1998 Dec;13(12):1814-21 [9844098.001]
  • [Cites] J Bone Miner Res. 1999 Oct;14(10):1672-9 [10491214.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):795-804 [10491415.001]
  • [Cites] Med Sci Sports Exerc. 2004 Oct;36(10):1789-95 [15595302.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):202-7 [15647813.001]
  • [Cites] Am J Public Health. 2005 Feb;95(2):236-7 [15671456.001]
  • [Cites] J Bone Miner Res. 2005 Mar;20(3):520-8 [15746998.001]
  • [Cites] Am J Public Health. 2003 Sep;93(9):1431-4 [12948957.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Sep;157(9):887-92 [12963594.001]
  • [Cites] Am J Prev Med. 2003 Nov;25(4):273-6 [14580626.001]
  • [Cites] Osteoporos Int. 2003 Oct;14(10):843-7 [12904837.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):e447 [14654643.001]
  • [Cites] Med Sci Sports Exerc. 2004 Jan;36(1):86-92 [14707773.001]
  • [Cites] Bone. 2004 Apr;34(4):755-64 [15050908.001]
  • [Cites] BMJ. 2004 Oct 9;329(7470):832-3 [15317729.001]
  • [Cites] Pediatrics. 1980 Dec;66(6):918-20 [7454482.001]
  • [Cites] J Clin Endocrinol Metab. 1990 May;70(5):1330-3 [2335574.001]
  • [Cites] Am J Prev Med. 2005 Oct;29(3):179-84 [16168866.001]
  • [Cites] Calcif Tissue Int. 2006 Feb;78(2):65-71 [16467972.001]
  • [Cites] Eur J Appl Physiol. 2006 Mar;96(5):587-92 [16408232.001]
  • [Cites] J Bone Miner Res. 2006 Jun;21(6):829-35 [16753013.001]
  • [Cites] J Pediatr. 2006 Jul;149(1):38-42 [16860124.001]
  • [Cites] Scand J Med Sci Sports. 2006 Aug;16(4):252-7 [16895530.001]
  • [Cites] Osteoporos Int. 2006 Dec;17(12):1726-33 [16983459.001]
  • [Cites] Pediatrics. 2006 Dec;118(6):e1627-34 [17142492.001]
  • [Cites] Scand J Med Sci Sports. 2007 Aug;17(4):340-7 [16774651.001]
  • [Cites] Acta Paediatr. 2000 Jun;89(6):637-43 [10914954.001]
  • (PMID = 17625016.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950706
  •  go-up   go-down


2. Linden C, Ahlborg HG, Besjakov J, Gardsell P, Karlsson MK: A school curriculum-based exercise program increases bone mineral accrual and bone size in prepubertal girls: two-year data from the pediatric osteoporosis prevention (POP) study. J Bone Miner Res; 2006 Jun;21(6):829-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A school curriculum-based exercise program increases bone mineral accrual and bone size in prepubertal girls: two-year data from the pediatric osteoporosis prevention (POP) study.
  • BMC (g) and areal BMD (aBMD; g/cm2) were measured with DXA of the total body (TB), the lumbar spine (L2-L4 vertebrae), the third lumbar vertebra (L3), the femoral neck (FN), and the leg.
  • The annual gain in BMC was greater in the intervention group than in the controls: L2-L4, mean 3.8 percentage points (p = 0.007); L3 vertebra, mean 7.2 percentage points (p < 0.001); legs, mean 3.0 percentage points (p = 0.07).
  • The intervention group had a greater annual gain in aBMD: total body, mean 0.6 percentage points (p = 0.006), L2-L4, mean 1.2 percentage points (p = 0.02), L3 vertebra, mean 1.6 percentage points (p = 0.006); legs, mean 1.2 percentage points (p = 0.007).

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753013.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Lakshminrusimha S, Russell JA, Steinhorn RH, Swartz DD, Ryan RM, Gugino SF, Wynn KA, Kumar VH, Mathew B, Kirmani K, Morin FC 3rd: Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen. Pediatr Res; 2007 Sep;62(3):313-8
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen.
  • The effect of resuscitation with varying levels of O2 on pulmonary hemodynamics at birth is not well known.
  • We hypothesized that the decrease in pulmonary vascular resistance (PVR) and subsequent response to pulmonary vasoconstrictors and vasodilators will differ following resuscitation with 21%, 50%, or 100% O2 for 30 min at birth in normal term lambs.
  • Lambs at 141 d gestation were delivered by cesarean section and ventilated with 21% (21% Res; n=6), 50% (50% Res; n=6), or 100% 02 (100% Res; n=7) for 30 min followed by ventilation with 21% O2 in all three groups.
  • A greater decrease in PVR was seen with 50% and 100% O2 ventilation than with 21% O2 (0.21 +/- 0.02, 0.21 +/- 0.02, and 0.34 +/- 0.05 mm Hg/mL/min/kg, respectively).
  • Subsequent pulmonary vasoconstriction to hypoxia (10% O2) and the thromboxane,analog U46619 (0.5 and 1 mcirog/kg/min) was similar in all three groups.
  • After inducing a stable elevation in PVR with U46619, impaired pulmonary vasodilation to inhaled NO (59 +/- 4, 65 +/- 4, and 74 +/- 5% of baseline PVR with 21, 50, and 100%Res, respectively) and acetylcholine infusion (67 +/- 8, 75 +/- 6, and 87 +/- 4% of baseline PVR with 21, 50, and 100%Res, respectively) and rebound pulmonary hypertension following their withdrawal were observed in the 100%Res group.
  • We conclude that, while ventilation with 100% O2 at birth results in a greater initial decrease in PVR, subsequent pulmonary vasodilation to NO/acetylcholine is impaired.

  • MedlinePlus Health Information. consumer health - Oxygen Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L2-10 [16085672.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 1;172(11):1393-8 [16141440.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L359-66 [16258003.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Mar 15;173(6):585-92 [16522763.001]
  • [Cites] Pediatrics. 2006 May;117(5):e978-88 [16618791.001]
  • [Cites] Pediatrics. 2006 May;117(5):e1029-38 [16651282.001]
  • [Cites] Pediatrics. 2006 Aug;118(2):789-92 [16882835.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L434-42 [10710514.001]
  • [Cites] Circ Res. 2000 Mar 17;86(5):534-40 [10720415.001]
  • [Cites] Br J Pharmacol. 2001 Jan;132(1):127-34 [11156569.001]
  • [Cites] Pediatr Res. 2001 Sep;50(3):423-9 [11518832.001]
  • [Cites] J Perinat Med. 2001;29(4):344-50 [11565204.001]
  • [Cites] J Pediatr. 2003 Mar;142(3):240-6 [12640369.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L322-33 [12665465.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Oct;29(4):465-71 [12714374.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1367-73 [15166009.001]
  • [Cites] Free Radic Biol Med. 2004 Nov 1;37(9):1384-92 [15454277.001]
  • [Cites] Pediatr Res. 1990 Apr;27(4 Pt 1):372-8 [2342829.001]
  • [Cites] Am J Physiol. 1993 Dec;265(6 Pt 1):L555-64 [8279572.001]
  • [Cites] Pediatr Res. 1998 Dec;44(6):843-9 [9853916.001]
  • [Cites] Gen Pharmacol. 1999 Apr;32(4):403-11 [10323480.001]
  • [Cites] Clin Perinatol. 1999 Sep;26(3):601-19 [10494467.001]
  • [Cites] J Physiol. 1952 Oct;118(2):45P-46P [13000753.001]
  • [Cites] J Physiol. 1953 Jul;121(1):141-62 [13085305.001]
  • [Cites] J Physiol. 1964 May;171:61-79 [14170145.001]
  • [Cites] J Physiol. 1964 May;171:80-9 [14170146.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Feb;288(2):L213-26 [15640520.001]
  • [Cites] Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):244-55 [15650412.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):F229-34 [15846013.001]
  • [Cites] Pediatr Res. 2005 May;57(5 Pt 1):631-6 [15774824.001]
  • [Cites] Pediatr Res. 2006 Jan;59(1):137-41 [16326983.001]
  • (PMID = 17622960.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL054705-11; United States / NHLBI NIH HHS / HL / R01 HL054705-10; United States / NHLBI NIH HHS / HL / HL-54705; United States / NHLBI NIH HHS / HL / R29 HL054705; United States / NHLBI NIH HHS / HL / R01 HL054705-11; United States / NHLBI NIH HHS / HL / HL054705-10; United States / NHLBI NIH HHS / HL / R01 HL054705
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide; 76898-47-0 / 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; N9YNS0M02X / Acetylcholine; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS34073; NLM/ PMC2150747
  •  go-up   go-down


Advertisement
4. Nordmark E, Josenby AL, Lagergren J, Andersson G, Strömblad LG, Westbom L: Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatr; 2008;8:54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parent's opinions about the children's performance of skills and activities and the amount of caregiver assistance were measured with Pediatric Evaluation Disability Inventory (PEDI).
  • RESULTS: The mean proportion of rootlets cut in S2-L2 was 40%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Med Child Neurol. 2000 Apr;42(4):245-52 [10795563.001]
  • [Cites] J Neurosurg Pediatr. 2008 Mar;1(3):180-6 [18352761.001]
  • [Cites] Childs Nerv Syst. 2001 Jan;17(1-2):1-18 [11219613.001]
  • [Cites] Dev Med Child Neurol. 2002 Jan;44(1):17-25 [11811645.001]
  • [Cites] Dev Med Child Neurol. 2002 Jan;44(1):26-33 [11811646.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):315-25 [12186459.001]
  • [Cites] Acta Paediatr. 2002;91(7):739-54 [12200898.001]
  • [Cites] JAMA. 2002 Sep 18;288(11):1357-63 [12234229.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):510-8 [12296632.001]
  • [Cites] J Paediatr Child Health. 2003 Jan-Feb;39(1):6-14 [12542805.001]
  • [Cites] Lakartidningen. 2003 Jan 16;100(3):125-30 [12596478.001]
  • [Cites] Acta Paediatr. 2003 Jun;92(6):648-52 [12856971.001]
  • [Cites] Lancet. 2004 May 15;363(9421):1619-31 [15145637.001]
  • [Cites] J Pediatr Orthop. 2004 Sep-Oct;24(5):529-36 [15308903.001]
  • [Cites] S Afr Med J. 1982 Jul 24;62(4):119-24 [7089801.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):178-84 [1988585.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):380-5 [1993902.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):745-9 [1738380.001]
  • [Cites] Dev Med Child Neurol. 1992 Jun;34(6):547-51 [1612216.001]
  • [Cites] Pediatr Neurosurg. 1992;18(1):43-7 [1419841.001]
  • [Cites] Dev Med Child Neurol. 1997 Mar;39(3):178-84 [9112967.001]
  • [Cites] Dev Med Child Neurol. 1997 Apr;39(4):214-23 [9183258.001]
  • [Cites] J Pediatr Orthop. 1998 Jan-Feb;18(1):69-74 [9449105.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):253-5 [9489542.001]
  • [Cites] Dev Med Child Neurol. 1998 Apr;40(4):220-32 [9593493.001]
  • [Cites] Dev Med Child Neurol. 1998 Apr;40(4):239-47 [9593495.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1014-9 [9609296.001]
  • [Cites] J Neurosurg. 2005 May;102(4 Suppl):363-73 [15926386.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1 Suppl):5-9 [16121998.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1 Suppl):10-6 [16121999.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):60-6 [15906043.001]
  • [Cites] J Pediatr Orthop B. 2006 Jul;15(4):244-6 [16751731.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1 Suppl):8-15 [16871864.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):1010-8 [16950992.001]
  • [Cites] Dev Med Child Neurol. 2007 Mar;49(3):163 [17355467.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6 Suppl):441-9 [17566400.001]
  • [Cites] Childs Nerv Syst. 2007 Sep;23(9):981-90 [17551739.001]
  • [Cites] Childs Nerv Syst. 2007 Sep;23(9):991-1002 [17643249.001]
  • [Cites] Pediatr Phys Ther. 2007 Fall;19(3):180-7 [17700346.001]
  • [Cites] Arch Dis Child. 2007 Sep;92(9):781-5 [17475694.001]
  • [Cites] Dev Med Child Neurol. 2007 Oct;49(10):751-6 [17880644.001]
  • [Cites] Med Care. 2007 Oct;45(10 Supl 2):S50-7 [17909384.001]
  • [Cites] BMC Pediatr. 2007;7:41 [18053264.001]
  • [Cites] Paediatr Anaesth. 2001 Jan;11(1):75-9 [11123736.001]
  • (PMID = 19077294.001).
  • [ISSN] 1471-2431
  • [Journal-full-title] BMC pediatrics
  • [ISO-abbreviation] BMC Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633339
  •  go-up   go-down


5. Papaioannou G, Young C, Owens CM: Multidetector row CT for imaging the paediatric tracheobronchial tree. Pediatr Radiol; 2007 Jun;37(6):515-29; quiz 612-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector row CT for imaging the paediatric tracheobronchial tree.
  • The introduction of multidetector row computed tomography (MDCT) scanners has altered the approach to imaging the paediatric thorax.
  • In an environment where the rapid acquisition of CT data allows general hospitals to image children instead of referring them to specialist paediatric centres, it is vital that general radiologists have access to protocols appropriate for paediatric applications.
  • Thus a dramatic reduction in the delivered radiation dose is ensured with optimal contrast bolus delivery and timing, and inappropriate repetition of the scans is avoided.
  • This article focuses on the main principles of volumetric CT imaging that apply generically to all MDCT scanners.
  • We describe the reconstruction techniques for imaging the paediatric thorax and the low-dose protocols used in our institution on a 16-slice detector CT scanner.
  • Examples of the commonest clinical applications are also given.
  • [MeSH-major] Bronchography / methods. Respiratory Tract Diseases / radiography. Trachea / radiography
  • [MeSH-minor] Bronchoscopy. Child. Child, Preschool. Contrast Media. Humans. Imaging, Three-Dimensional. Infant. Infant, Newborn. Radiation Dosage. Radiographic Image Interpretation, Computer-Assisted. Tomography, X-Ray Computed. User-Computer Interface

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Radiol. 2000 Apr;34(1):9-25 [10802203.001]
  • [Cites] Eur Radiol. 2004 Mar;14 Suppl 4:L2-12 [14752574.001]
  • [Cites] Pediatr Radiol. 2001 Dec;31(12):836-40 [11727016.001]
  • [Cites] Pediatrics. 2003 Oct;112(4):971-2 [14523193.001]
  • [Cites] Chest. 2003 Nov;124(5):1834-40 [14605057.001]
  • [Cites] Radiology. 2003 Dec;229(3):641-50 [14563904.001]
  • [Cites] Paediatr Anaesth. 2004 Jan;14(1):60-74 [14717876.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):e17 [14610245.001]
  • [Cites] Chest. 2004 Feb;125(2):704-11 [14769755.001]
  • [Cites] Pediatr Pulmonol. 2004 Aug;38(2):168-73 [15211702.001]
  • [Cites] Postgrad Med J. 2004 Jul;80(945):420-3 [15254308.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1400-5 [15133710.001]
  • [Cites] Pediatr Pulmonol. 1998 Feb;25(2):133-5 [9516099.001]
  • [Cites] Eur Radiol. 1998;8(3):335-51 [9510562.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1771-7 [15547227.001]
  • [Cites] Pediatr Radiol. 2001 Apr;31(4):269-78 [11321746.001]
  • (PMID = 17457581.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 16
  • [Other-IDs] NLM/ PMC1891645
  •  go-up   go-down


6. Balamurugan S, Sugapriya D, Shanthi P, Thilaka V, Venkatadesilalu S, Pushpa V, Madhavan M: Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias. Indian J Hematol Blood Transfus; 2007 Dec;23(3-4):73-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias.
  • We have studied MDR1 expression and AgNORS in 41 cases of acute leukemia in children.
  • In this study, AgNOR counts in patients with acute lymphoblastic leukemia (ALL) L2 subtype (FAB classification) were significantly higher as compared to the ALL L1 subtype.
  • Similarly, mean AgNOR count in the acute myeloid Leukemia (AML) M2 subtype was significantly higher as compared to the ALL L1 subtype.
  • However, there was no correlation between AgNOR and treatment outcome or between AgNOR counts and MDR1 expression in any of the subtypes of acute leukemia included in this series.
  • This would suggest that factors other than MDR1 may be of relevance in Pediatric ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Blood. 1992 Jan 15;79(2):295-8 [1346094.001]
  • [Cites] Blood. 1992 Jan 15;79(2):473-6 [1370388.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):50-3 [1671821.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1237-47 [8644864.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1202-10 [12663440.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1201-7 [15547738.001]
  • [Cites] J Pathol. 1989 Jul;158(3):185-8 [2475599.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):553-61 [6938236.001]
  • [Cites] Blood. 1993 May 1;81(9):2394-8 [8097634.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3480-1 [8507883.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):135-40 [8574159.001]
  • [Cites] Cancer Lett. 1996 Nov 12;108(1):87-91 [8950214.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1673-80 [9324288.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1512-8 [9552060.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):149-52 [10367797.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):309-14 [11999562.001]
  • [Cites] Mol Cancer Res. 2004 Jun;2(6):339-47 [15235109.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51 [15494300.001]
  • (PMID = 23100919.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453125
  • [Keywords] NOTNLM ; Acute leukemia / AgNOR / Multidrug Resistance 1 / P-glycoprotein
  •  go-up   go-down


7. Morley SC, Weber KS, Kao H, Allen PM: Protein kinase C-theta is required for efficient positive selection. J Immunol; 2008 Oct 1;181(7):4696-708
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We decided to re-evaluate the role of PKCtheta in thymocyte development using the well-characterized class II-restricted n3.L2 TCR-transgenic TCR model.
  • Analysis of n3.L2 PKCtheta(-/-) mice revealed a defect in thymocyte-positive selection, resulting in a 50% reduction in the generation of n3.L2 CD4 single-positive thymocytes and n3.L2 CD4 mature T cells.
  • Competition between n3.L2 WT and n3.L2 PKCtheta(-/-) thymocytes in bone marrow chimeras revealed a more dramatic defect, with a >80% reduction in generation of n3.L2 CD4 single-positive thymocytes derived from PKCtheta(-/-) mice.
  • Inefficient positive selection of n3.L2 PKCtheta(-/-) CD4 single-positive cells resulted from "weaker" signaling through the TCR and correlated with diminished ERK activation.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 23;404(6776):402-7 [10746729.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):3116-24 [9915850.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2410-4 [10946265.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5004-10 [11046028.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):678-89 [11134353.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4966-73 [11673503.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6270-8 [11714790.001]
  • [Cites] Annu Rev Immunol. 2002;20:761-94 [11861617.001]
  • [Cites] Immunity. 2002 Jun;16(6):839-48 [12121665.001]
  • [Cites] Biochem J. 2003 Mar 1;370(Pt 2):497-503 [12435268.001]
  • [Cites] Science. 1999 Jul 9;285(5425):221-7 [10398592.001]
  • [Cites] J Exp Med. 2004 Nov 1;200(9):1167-77 [15520247.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 3;325(1):133-43 [15522211.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):149-58 [15630142.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):992-1000 [15592506.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4426-41 [15899849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13574-9 [16174747.001]
  • [Cites] J Mol Biol. 2006 Jan 20;355(3):347-59 [16309697.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1806-16 [16479000.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6709-16 [16709830.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1886-93 [16849501.001]
  • [Cites] Cell Mol Immunol. 2006 Aug;3(4):263-70 [16978534.001]
  • [Cites] Immunity. 2006 Oct;25(4):571-81 [17045823.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):724-9 [17086201.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):953-60 [17202357.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):388-97 [17322886.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4603-16 [17485448.001]
  • [Cites] Pharmacol Res. 2007 Jun;55(6):537-44 [17544292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16257-62 [17901205.001]
  • [Cites] J Exp Med. 2007 Oct 29;204(11):2513-20 [17908937.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6836-44 [17982074.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):731-5 [18046413.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4406-16 [17846228.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1442-50 [18209039.001]
  • [Cites] Immunol Rev. 2003 Apr;192:64-79 [12670396.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1525-35 [12782715.001]
  • [Cites] Curr Biol. 2003 Jul 15;13(14):1252-8 [12867038.001]
  • [Cites] Biochem J. 2003 Dec 15;376(Pt 3):545-52 [14570590.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):164-71 [14673152.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):289-98 [14770179.001]
  • [Cites] Immunity. 2004 Mar;20(3):255-66 [15030770.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4235-44 [15034036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4566-71 [15070758.001]
  • [Cites] Adv Immunol. 2004;83:91-131 [15135629.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6634-41 [15153478.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(14):6501-13 [15226449.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):181-9 [15263025.001]
  • [Cites] Annu Rev Immunol. 2003;21:139-76 [12414722.001]
  • [Cites] Nat Immunol. 2004 Aug;5(8):785-90 [15282562.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5434-44 [15494490.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):8339-43 [2186042.001]
  • [Cites] Nature. 1993 May 13;363(6425):156-9 [8483498.001]
  • [Cites] Cell. 1994 Dec 2;79(5):913-22 [8001128.001]
  • [Cites] Immunity. 1994 Jun;1(3):197-205 [7889408.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):3835-43 [9558088.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):585-93 [9670931.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):82-6 [9738502.001]
  • [Cites] Immunity. 1998 Oct;9(4):565-74 [9806642.001]
  • [Cites] Nature. 2000 Jul 27;406(6794):426-30 [10935641.001]
  • (PMID = 18802072.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI024157-21; United States / NIAID NIH HHS / AI / R37 AI024157; United States / NIAID NIH HHS / AI / R37 AI024157-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Isoenzymes; EC 2.7.1.- / Prkcq protein, mouse; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ NIHMS80199; NLM/ PMC2645034
  •  go-up   go-down


8. Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol; 2009 Jun;31(6):385-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
  • The importance of maintenance therapy for higher risk childhood acute lymphoblastic leukemia (ALL) is uncertain.
  • Between 1992 and 2001 the Nordic Society for Pediatric Haematology/Oncology compared in a nonrandomized study conventional oral methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy with a multidrug cyclic LSA2L2 regimen.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Methotrexate / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2009 Jun;31(6):383-4 [19648785.001]
  • (PMID = 19648786.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


9. Subotic U, Holland-Cunz S, Bardenheuer M, Loff S, Wessel LM: Chance fracture--a rare injury in pediatric patients? Eur J Pediatr Surg; 2007 Jun;17(3):207-9
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chance fracture--a rare injury in pediatric patients?
  • She suffered severe polytrauma with torn abdominal muscles, rupture of the mesenteric arteries, bowel and bladder, hematoma at the right colonic flexure and disruption of the intervertebral ligaments L2/L3, including the intervertebral disc, typical of Chance fracture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638162.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Pludowski P, Jaworski M, Matusik H, Kobylinska M, Klimek P, Lorenc RS: The evaluation of consistency between body composition assessments in pediatric population using pencil beam and fan beam dual-energy x-ray absorptiometers. J Clin Densitom; 2010 Jan-Mar;13(1):84-95
MedlinePlus Health Information. consumer health - Bone Density.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of consistency between body composition assessments in pediatric population using pencil beam and fan beam dual-energy x-ray absorptiometers.
  • Therefore, the study was aimed at investigating the consistency of bone and body composition measures performed in pediatric population using pencil beam (DPX-L; GE Healthcare, GE Healthcare, Madison, WI) and fan beam (Prodigy; GE Healthcare, GE Healthcare, Madison, WI) densitometers.
  • Total body (TB) and lumbar spine (S) (L2-L4) measurements were performed using DPX-L and Prodigy during the same visit.
  • The results of this study document a necessity for implementation of calculated cross-calibration equations to transform DPX-L-based local pediatric references into a novel Prodigy system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20171570.001).
  • [ISSN] 1094-6950
  • [Journal-full-title] Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
  • [ISO-abbreviation] J Clin Densitom
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. López-Hernández MA, Alvarado-Ibarra M, Jiménez-Alvarado RM, De Diego-Flores JE, González-Avante CM: [Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol]. Gac Med Mex; 2008 Nov-Dec;144(6):485-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol].
  • OBJECTIVE: To ascertain the efficacy and safety of two chemotherapy regimens, one designed for adults and the other for children, in adolescent patients with acute lymphoblastic leukemia (ALL).
  • Predominant in both groups was L2 morphology and B-cell CD10(+) immunophenotype.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Clinical Protocols. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112720.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


12. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • However, there are few reports dealing with various pediatric malignant tumors.
  • In the current study, we analyzed the diagnostic value of AFP fractions for pediatric diseases, in particular, those occurring in the neoinfantile period.
  • In our analytical system (LiBASys), the level of the L3 fraction contains the majority of the L2 fraction.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Nawaz A, Matta H, Hamchou M, Jacobsz A, Al Salem AH: Camel-related injuries in the pediatric age group. J Pediatr Surg; 2005 Aug;40(8):1248-51
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Camel-related injuries in the pediatric age group.
  • One child had L2 and L3 dislocation, with displacement and compression fracture of L2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080927.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nagatoshi Y, Matsuzaki A, Suminoe A, Inada H, Ueda K, Kawakami K, Yanai F, Nakayama H, Moritake H, Itonaga N, Hotta N, Fujita K, Hidaka Y, Yamanaka T, Kawano Y, Okamura J: Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 Aug;55(2):239-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
  • BACKGROUND: A total of 201 pediatric cases of acute lymphoblastic leukemia were treated with the ALL-96 protocol by the Kyushu-Yamaguchi Children's Cancer Study Group.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582970.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


15. Athanassiadou F, Tragiannidis A, Rousso I, Katsos G, Sidi V, Koliouskas D, Papastergiou C, Tsituridis I: Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment. Pediatr Hematol Oncol; 2005 Jun;22(4):285-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.
  • Osteopenia and osteoporosis are currently receiving particular attention as late effects of therapy in survivors of childhood acute lymphoblastic leukemia (ALL).
  • Lumbar spine (L2-L4) bone mineral density (BMD, g/cm(2)) was measured by dual energy X-ray absorptiometry in 20 children with ALL, a median of 25.9 months postdiagnosis and results were expressed as z-scores relative to healthy Caucasian children (controls).
  • [MeSH-major] Bone Diseases, Metabolic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020115.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


16. Jeon IS, Yi DY: Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus. Pediatr Hematol Oncol; 2009 Mar;26(2):85-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
  • Acute lymphoblastic leukemia (ALL), a primary hematologic malignancy that is especially common in childhood, occurs relatively rarely as a secondary malignant neoplasm.
  • ALL, FAB L2, and immunophenotypically pro-B developed 16 months after the final chemotherapy treatment.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Perivascular Epithelioid Cell Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Uterine Neoplasms / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322738.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


17. Tekgul H, Dizdarer G, Demir N, Ozturk C, Tutuncuoglu S: Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement. J Pediatr Endocrinol Metab; 2005 Jun;18(6):585-8
Hazardous Substances Data Bank. CHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BMD measurements were made from lumbar spine (L2-L4) regions.

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042326.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


18. Pekmezci M, Yilmaz G, Daglioglu K, Gulsen M, Alanay A, Acaroglu E, Yazici M: The effect of anterior spinal fusion on spinal canal development in an immature porcine model. Spine (Phila Pa 1976); 2009 Jul 1;34(15):E501-6
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spinal canal area was measured at the control level (CL) (L2), arthrodesis level (AL) (L4), superior (L3), and inferior (L5) instrumented level (SIL and IIL).
  • The average area of L2 (CL) was 0.56 +/- 0.06 cm before surgery.
  • At the final follow-up the average area of L2 was 1.20 cm.
  • Although, it is difficult to directly extrapolate these findings to clinical practice, the spine surgeons operating on pediatric patients should be aware of this possibility.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564754.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Léger J: Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics; 2005 Jul;116(1):e102-8
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
  • OBJECTIVES: Abnormalities in bone mineral density (BMD), body composition, and bone metabolism have been reported in children who were treated for acute lymphoblastic leukemia (ALL) during and after completion of therapy.
  • METHODS: BMD of total body (TB; g/cm(2)), areal and apparent volumetric lumbar spine (L2-L4), lean body mass, and percentage of body fat were measured by dual-energy x-ray absorptiometry in 37 children (median age: 7.9 years; range: 4.7-20.6 years) who were treated for ALL at a median age of 3.3 years (range: 1.1-16.6 years), after a median time of 2.2 years after the completion of treatment, and after a 1-year follow-up period.
  • RESULTS: A slight decrease in TB BMD was found after a median time of 2.2 years after the completion of therapy for ALL in childhood.
  • [MeSH-major] Body Composition. Bone Density. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


20. Ban SP, Park SH, Wang KC, Cho BK, Phi JH, Lee JY, Kim SK: Congenital paraspinal Ewing sarcoma family of tumors with an epidural extension. J Clin Neurosci; 2010 Dec;17(12):1599-601
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whole-spine MRI scans showed a paraspinal mass with an epidural extension from the T11 to L2 levels, causing severe spinal cord compression.
  • A second operation was performed with a laminectomy from the T11 to L2 levels, and the epidural mass was radically resected.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20817468.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


21. Ambroszkiewicz J, Klemarczyk W, Gajewska J, Chełchowska M, Franek E, Laskowska-Klita T: The influence of vegan diet on bone mineral density and biochemical bone turnover markers. Pediatr Endocrinol Diabetes Metab; 2010;16(3):201-4
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is especially important in childhood and adolescence, when growth and bone turnover are most intensive.
  • Z-score BMD lumbar spine (L2-L4) was between -0.9 to -1.9 in parents and -1.5 to -1.7 in children.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Vegetarian Diet.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092700.001).
  • [ISSN] 2081-237X
  • [Journal-full-title] Pediatric endocrinology, diabetes, and metabolism
  • [ISO-abbreviation] Pediatr Endocrinol Diabetes Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Phosphates; 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  •  go-up   go-down


22. Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O, Dworzak M, Gadner H, Austrian Berlin-Frankfurt-Münster (BFM) Group: Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol; 2006 Apr-May;23(3):167-76
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping.
  • Non-Hodgkin lymphoma (NHL) represents one of the most rapidly growing malignancies in childhood and adolescence.
  • The authors identified 23 patients with Burkitt lymphoma by the combination of FAB L3 morphology and a mature B-cell phenotype and 22 patients with lymphoblastic lymphoma by FAB L1/L2 morphology and a T-/B-cell precursor phenotype.
  • Burkitt lymphoma, lymphoblastic lymphoma, and, in a few cases, some large cell lymphomas could be classified reliably by cytomorphology and immunophenotyping of freshly obtained tumor cell material, enabling an early start of specific lymphoma treatment.
  • [MeSH-minor] Abdominal Neoplasms / classification. Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / pathology. Adolescent. Antigens, CD / analysis. Austria / epidemiology. Biopsy, Fine-Needle. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Cell Nucleus / ultrastructure. Cell Size. Child. Child, Preschool. Cytoplasm / ultrastructure. Early Diagnosis. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Lymphocyte Subsets / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prospective Studies. Staining and Labeling


23. Schmidt S, Mellström D, Norjavaara E, Sundh SV, Saalman R: Low bone mineral density in children and adolescents with inflammatory bowel disease: a population-based study from Western Sweden. Inflamm Bowel Dis; 2009 Dec;15(12):1844-50
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BMD values were expressed as Z-scores using normative pediatric data from Lunar (GE Medical Systems).
  • The entire IBD group showed significantly lower BMD Z-scores of the lumbar spine (L2-L4) in comparison to healthy references (-0.8 standard deviation [SD], range -5.9 to 3.7 SD, P < 0.001).
  • CONCLUSIONS: Low BMD is prevalent in Swedish pediatric patients with IBD.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
  • (PMID = 19408319.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine
  •  go-up   go-down


24. Woodhouse CR: Myelomeningocele: neglected aspects. Pediatr Nephrol; 2008 Aug;23(8):1223-31
Genetic Alliance. consumer health - Meningomyelocele.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those who walk in childhood have a 20-50% chance of becoming wheelchair dependent as adults.
  • It is essential that safe and manageable urine drainage is established in childhood: the bladder never improves with time, and surgical reconstruction becomes progressively more difficult.
  • Independence in adult life will only be possible with intense preparation in childhood.
  • Children who are continent and have lesions below L2 are likely to have normal sexual function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Orthop. 2000 Jan-Feb;20(1):82-7 [10641695.001]
  • [Cites] Artif Organs. 1999 Feb;23(2):139-42 [10027882.001]
  • [Cites] J Epidemiol Community Health. 2000 Sep;54(9):660-6 [10942444.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 2):958-61 [10958716.001]
  • [Cites] Arch Dis Child. 2000 Oct;83(4):293-7 [10999858.001]
  • [Cites] J Reprod Med. 2000 Sep;45(9):743-8 [11027084.001]
  • [Cites] J Pediatr. 2001 Dec;139(6):880-6 [11743519.001]
  • [Cites] Am J Respir Crit Care Med. 2003 May 15;167(10):1451; author reply 1451 [12738602.001]
  • [Cites] BMJ. 2003 Jun 21;326(7403):1365-6 [12816823.001]
  • [Cites] J Urol. 2004 Apr;171(4):1659-62 [15017261.001]
  • [Cites] Clin Rehabil. 2004 Mar;18(2):178-85 [15053127.001]
  • [Cites] Dev Med Child Neurol. 2004 Apr;46(4):244-52 [15077702.001]
  • [Cites] Childs Nerv Syst. 2004 Jun;20(6):392-6 [15071749.001]
  • [Cites] Br Med J. 1973 Oct 27;4(5886):197-201 [4586034.001]
  • [Cites] Dev Med Child Neurol Suppl. 1975;(35):123-8 [1107110.001]
  • [Cites] J Child Psychol Psychiatry. 1977 Aug;18(3):229-37 [330550.001]
  • [Cites] J Urol. 1986 Aug;136(2):425-6 [3735508.001]
  • [Cites] J Urol. 1987 May;137(5):829-36 [3553617.001]
  • [Cites] Int J Eat Disord. 1999 May;25(4):457-61 [10202657.001]
  • [Cites] Int J Rehabil Res. 1999 Mar;22(1):71-4 [10207756.001]
  • [Cites] BMJ. 1999 Jul 10;319(7202):92-3 [10398632.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):125-6 [10408490.001]
  • [Cites] Dev Med Child Neurol. 1999 Jul;41(7):446-9 [10454227.001]
  • [Cites] Arch Phys Med Rehabil. 2005 May;86(5):979-87 [15895345.001]
  • [Cites] J Rehabil Med. 2006 May;38(3):192-200 [16702087.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1987 Aug;25(4):341-5 [3653497.001]
  • [Cites] Dev Med Child Neurol. 1990 Feb;32(2):108-18 [2186948.001]
  • [Cites] Lancet. 1991 Jul 20;338(8760):131-7 [1677062.001]
  • [Cites] Pediatrics. 1991 Aug;88(2):280-5 [1861926.001]
  • [Cites] Br J Urol. 1992 Jun;69(6):589-93 [1638344.001]
  • [Cites] N Engl J Med. 1992 Dec 24;327(26):1832-5 [1307234.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):687-90 [8326623.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):691-3 [8326624.001]
  • [Cites] BMJ. 1993 Sep 18;307(6906):703-6 [8401091.001]
  • [Cites] J La State Med Soc. 1993 Sep;145(9):394-6, 399-402 [8263379.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1993 Nov;52(1):63-70 [8119478.001]
  • [Cites] Br J Obstet Gynaecol. 1994 Mar;101(3):197-202 [8193092.001]
  • [Cites] JAMA. 1996 Apr 10;275(14):1093-6 [8601928.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):777-9 [8976778.001]
  • [Cites] J Urol. 1998 Nov;160(5):1775-8 [9783950.001]
  • [Cites] BMJ. 1999 Feb 20;318(7182):518-21 [10024264.001]
  • [Cites] Eur J Pediatr Surg. 1999 Dec;9 Suppl 1:31-2 [10661789.001]
  • (PMID = 18200450.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC2441590
  •  go-up   go-down


25. Muszyńska-Rosłan K, Konstantynowicz J, Krawczuk-Rybak M: [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia]. Pol Merkur Lekarski; 2007 Oct;23(136):271-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
  • Chemotherapeutic agents such as glucocorticoids, methotrexate, antymetabolities, cranial and local irradiation) may severely disturb normal growth, bone mineral acquisition and skeletal development because the most individuals go through the stages of rapid growth when childhood acute lymphoblastic leukemia (ALL) is diagnosed.
  • AIM OF THE STUDY: Analysis of the bone density accretion in children and adolescents in various time after tretament for acute lymphoblastic leukemia.
  • MATERIALS AND METHODS: We examined 107 patients (70 males) who had been treated for ALL according to the protocol of the Polish Pediatric Leukemia, Lymphoma Study Group.
  • History of fractures, bone mineral density (BMD) measurements of lumbar spine (L2-L4) and total body were performed using dual-energy x-ray absorptiometry (GE Medical Systems Lunar DPX-L), expressed as g/cm2 and compared to reference values obtained from the 473 age - and gender-matched healthy children from the same region of Poland.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Density / drug effects. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


26. Tanyeli A, Erbey F, Bayram I, Kömür M: Myeloid antigen positivity in Turkish children with acute lymphoblastic leukemia lacks influence on prognosis. Asian Pac J Cancer Prev; 2010;11(6):1823-6
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid antigen positivity in Turkish children with acute lymphoblastic leukemia lacks influence on prognosis.
  • INTRODUCTION: Several studies have suggested that the presence of myeloid antigens is a poor prognostic factor in patients with acute lymphoid leukemia (ALL).
  • MATERIALS AND METHODS: Seventy-three children with a diagnosis of ALL-L1 and 38 with ALL-L2 were included.
  • RESULTS: Myeloid antigens were positive in 48.4% with ALL-L1 and 60.5% with ALL-L2, the difference not being significant.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / metabolism. Antigens, Surface / metabolism. Biomarkers, Tumor / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338240.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Glard Y, Launay F, Viehweger E, Hamel A, Jouve JL, Bollini G: Neurological classification in myelomeningocele as a spine deformity predictor. J Pediatr Orthop B; 2007 Jul;16(4):287-92
Genetic Alliance. consumer health - Meningomyelocele.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Groups were defined as follows: group I, L5 or below (meaning that all the patients in this group have a paralysis that at least leaves the L5 segment intact); group II, L3-L4; group III, L1-L2; group IV, T12 and above (meaning that all the patients in this group have a paralysis that reaches T11 or above).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527108.001).
  • [ISSN] 1060-152X
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Hasanbegović E: [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)]. Med Arh; 2006;60(5):315-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)].
  • We report about very rare case of ten years old boy with diagnose of acute myeloic leukaemia which was diagnosed in his age of five (March of 2000) at Pediatric Clinic in Sarajevo.
  • Just 7 months after transplantation boy had relaps of illness in the form of acute lymphoblastic leukaemia (ALL/L2).
  • Complete therapeutic protocol for acute lymphoblastic leukaemia was done and now boy is in complete clinical and hematologic remission.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944736.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


29. Amouee A, Memarzadeh M, Ashrafi M, Farid M, Sanei MH, Soroori S, Vahed E, Yadegari M: The effects of amniotic fluid on the histopathologic changes of exposed spinal cord in fetal sheep. Arch Iran Med; 2009 Jan;12(1):35-40
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the sheep at 90 - 100 days of gestation (term: 145 - 150 days) the lumbar skin was incised, paraspinal soft tissues were excised, laminectomy was performed at L2 - L4, and dura matter was opened.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111027.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


30. Rossi JG, Felice MS, Bernasconi AR, Ribas AE, Gallego MS, Somardzic AE, Alfaro EM, Alonso CN: Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma; 2006 Apr;47(4):715-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome.
  • Considering that leukemias in childhood and in adults are different diseases, we describe three pediatric cases to help compare the biological characteristics, immunophenotype, clinical features, treatment response and incidence of this disease in both age groups.
  • From a total 1363 new patients with acute leukemia (AL), we report three cases with blasts of French - American - British L2 morphology, an absence of the most specific markers for myeloid, T or B lineage and lacking CD34, which led us to evaluate the blasts with an extensive panel of antibodies, including those related to the other putative pathways of lymphoid differentation: natural killer and DC.
  • All three children showed good response to acute lymphoblastic leukemia (ALL) protocols, achieving complete remission even when one of the patients relapsed and received an allogeneic transplant.
  • [MeSH-major] Dendritic Cells / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690531.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down






Advertisement